Roche Expected To File Second Anti-Generic Suit In India
This article was originally published in PharmAsia News
Executive Summary
Roche is stepping up its legal fight against India's Cipla over the latter's attempts to market a generic of Valcyte (valganciclovir) for treating HIV/AIDS infections. Roche is expected to intensify the fight by filing in the Madras high court, adding to its legal efforts against Cipla. Another suit already has been filed in the Delhi high court, seeking an injunction against Cipla on grounds its generic infringes on the patent for Tarceva (erlotinib), Roche's anti-cancer drug. The Valcyte suit is expected to be filed in the Madras court because it was patented in the Chennai patent office. (Click here for more